Related to AstraZeneca Teams Up with U.K. Cancer Institutes to Target Molecular Chaperones

• Chemotherapy for the 21st Century
  After a century of using body surface area, oncologists are warming to maximum-tolerated exposure for determining cancer drug dosages.
  
• Getting Cancer Immunotherapeutics Approved
  It’s not just the FDA standing in the way.
  
• 15 Breast Cancer Drugs in the Pipeline Right Now
  Which candidates are on their way from the lab to the medicine chests of thousands?
  
• Genome Testing Reduces Overtreatment
  Study after study has shown that molecular diagnostics can help oncologists more effectively treat patients.
  
• Biggest Biotech Trends of 2012
  GEN takes a look back at some key biopharma developments of the past 12 months.
  
• 10 Predictions That Will Transform Healthcare
  Peer into GEN's crystal ball for a glimpse of what's to come.
  
• DNA Methylation Rules: Studying Epigenetics with New Tools
  The tools to unravel the epigenetic control mechanisms that influence how cells control access of transcriptional proteins to DNA are just beginning to emerge.
  
• Women and Smoking
  Looking for a reason to quit, ladies? Look no further.
  
• Performing “Informative Clinical Trials” in Mice
  Patient-derived tumor xenografts: better than cancer cell lines for preclinical testing in animal models?
  
• Cancer Model Database Emerges from WOMB
  Oncology researchers wishing for a tool to help them find available models and services may have had their prayers answered.
  
• Literature Review: Which Drug Combination Will Unlock Triple-Negative Breast Cancer?
  Researchers describe a strategy for treating TNBC that combines noncompetitive antibodies to achieve degradation of EGFR and tumor inhibition.
  
• Detecting Acquired Drug Resistance in Cancer
  New methods allow noninvasive analysis in blood plasma.
  
• The Tumor Microenvironment as a Drug Target: Chasing Slippery Targets
  This first part of a two-part series discusses how researchers are looking at ways to attack tumors by targeting the cellular frameworks that keep them alive.
  
• The Tumor Microenvironment as a Drug Target, Part II
  In the search for new targets, cancer researchers are taking a closer look at the cellular support networks that allow tumors to survive.
  
• Literature Review: A Step Closer to Personalized Medicine
  Researchers use patient-specific cell lines derived in mice to personalize chemotherapy.
  
• Moving Genomics Closer to the Clinic
  Foundation Medicine and Memorial Sloan-Kettering Cancer Center are working to translate genomic information into personalized cancer treatment.
  
• Cancer’s Bitter Medicine
  CML experts raise industry hackles by decrying high-and-rising cost of treatments.
  
• Targeting Deranged Metabolism to Treat Cancer
  Scientists are investigating how genes controlling metabolism are connected with cancers.
  
• Editor’s Note: Myriad, the Supreme Court, and Gene Patents
  GEN's John Sterling weighs in.
  
• Avastin: Time for a Predictive Test
  Roche’s strategy to expand the use of Avastin into the first-line and adjuvant settings is particularly dependent on identifying those most likely to see a benefit.